0001593968-22-000613.txt : 20220303 0001593968-22-000613.hdr.sgml : 20220303 20220303160620 ACCESSION NUMBER: 0001593968-22-000613 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220301 FILED AS OF DATE: 20220303 DATE AS OF CHANGE: 20220303 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Hopper Jonathan Mark CENTRAL INDEX KEY: 0001626325 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35280 FILM NUMBER: 22708668 MAIL ADDRESS: STREET 1: 64 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Vericel Corp CENTRAL INDEX KEY: 0000887359 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 943096597 STATE OF INCORPORATION: MI FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 64 SIDNEY ST. CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 7349305555 MAIL ADDRESS: STREET 1: 64 SIDNEY ST. CITY: CAMBRIDGE STATE: MA ZIP: 02139 FORMER COMPANY: FORMER CONFORMED NAME: AASTROM BIOSCIENCES INC DATE OF NAME CHANGE: 19960428 4 1 primary_01.xml PRIMARY DOCUMENT X0306 4 2022-03-01 0000887359 Vericel Corp VCEL 0001626325 Hopper Jonathan Mark C/O VERICEL CORPORATION 64 SIDNEY STREET CAMBRIDGE MA 02139 false true false false Chief Medical Officer Common Stock 2022-03-01 4 M false 10000 10.95 A 55914 D Common Stock 2022-03-01 4 S false 10000 41.406 D 45914 D Common Stock 2022-03-01 4 M false 10000 18 A 55914 D Common Stock 2022-03-01 4 S false 6738 41.462 D 49176 D Stock Option (right to buy) 10.95 2022-03-01 4 M false 10000 0 D 2028-08-20 Common Stock 10000 37604 D Stock Option (right to buy) 18 2022-03-01 4 M false 10000 0 D 2030-02-11 Common Stock 10000 38750 D These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 11, 2021. These options, representing the right to purchase 135,000 shares, became exercisable on August 20, 2019, the first anniversary of the date of grant, with 25% vesting and the remaining 75% vesting in equal quarterly installments over three years thereafter, contingent upon continued service to the Company. These options, representing the right to purchase 48,750 shares, became exercisable in quarterly installments, contingent upon continued service to the Company, with the first vesting date on May 11, 2020. /s/ Sean Flynn, as Attorney-in-Fact for Jonathan Hopper 2022-03-03